Published: January 2020 | Report Code: LS11991 | Available Format: PDF | Pages: 198
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Type
1.3.2 Market Segmentation by Vector Type
1.3.3 Market Segmentation by Application
1.3.4 Market Segmentation by End User
1.3.5 Market Segmentation by Geography
1.3.6 Analysis Period
1.3.7 Market Data Reporting Unit
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research by Industry Participant
2.2.2 Breakdown of Primary Research by Company Type
2.3 Baseline Methodology
2.4 Market Size Estimation
2.5 KOLs’ Sources
2.6 Data Triangulation
2.7 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Type
4.1.1.1 In vivo
4.1.1.2 Ex vivo
4.1.2 By Vector Type
4.1.2.1 Viral
4.1.2.1.1 AAV
4.1.2.1.2 Lentivirus
4.1.2.1.3 Adenovirus
4.1.2.1.4 Retrovirus
4.1.2.1.5 Others
4.1.2.2 Non-viral
4.1.2.3 Others
4.1.3 By Application
4.1.3.1 Oncology
4.1.3.2 Rare diseases
4.1.3.3 Neurology
4.1.3.4 Ophthalmology
4.1.3.5 Hematology
4.1.3.6 Infectious diseases
4.1.3.7 Cardiology
4.1.3.8 Others
4.1.4 By End User
4.1.4.1 Pharmaceutical and biotechnology companies
4.1.4.2 Academic institutes and research centers
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of collaborations and partnerships
4.2.1.2 Evolution of the market with product launches
4.2.1.3 Outsourcing vector and gene therapy manufacturing
4.2.2 Drivers
4.2.2.1 Positive clinical results
4.2.2.2 Increasing therapy development activities
4.2.2.3 Surging burden of chronic diseases
4.2.2.4 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Cost-ineffectiveness of gene therapies
4.2.3.2 Long-term safety issues
4.2.3.3 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Advances in the manufacturing facility
4.3 Porter’s Five Forces Analysis
Chapter 5. Global Market Size and Forecast
5.1 By Type
5.2 By Vector Type
5.2.1 Viral Vector Market, by Type
5.3 By Application
5.4 By End User
5.5 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Type
6.2 By Vector Type
6.2.1 Viral Vector Market, by Type
6.3 By Application
6.4 By End User
6.5 By Country
6.5.1 U.S. Gene Therapy Market
6.5.1.1 By type
6.5.1.2 By vector type
6.5.1.2.1 Viral vector market, by type
6.5.1.3 By application
6.5.1.4 By end user
6.5.2 Canada Gene Therapy Market
6.5.2.1 By type
6.5.2.2 By vector type
6.5.2.2.1 Viral vector market, by type
6.5.2.3 By application
6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Type
7.2 By Vector Type
7.2.1 Viral Vector Market, By Type
7.3 By Application
7.4 By End User
7.5 By Country
7.5.1 Germany Gene Therapy Market
7.5.1.1 By type
7.5.1.2 By vector type
7.5.1.2.1 Viral vector market, by type
7.5.1.3 By application
7.5.1.4 By end user
7.5.2 U.K. Gene Therapy Market
7.5.2.1 By type
7.5.2.2 By vector type
7.5.2.2.1 Viral vector market, by type
7.5.2.3 By application
7.5.2.4 By end user
7.5.3 France Gene Therapy Market
7.5.3.1 By type
7.5.3.2 By vector type
7.5.3.2.1 Viral vector market, by type
7.5.3.3 By application
7.5.3.4 By end user
7.5.4 Italy Gene Therapy Market
7.5.4.1 By type
7.5.4.2 By vector type
7.5.4.2.1 Viral vector market, by type
7.5.4.3 By application
7.5.4.4 By end user
7.5.5 Spain Gene Therapy Market
7.5.5.1 By type
7.5.5.2 By vector type
7.5.5.2.1 Viral vector market, by type
7.5.5.3 By application
7.5.5.4 By end user
Chapter 8. APAC Market Size and Forecast
8.1 By Type
8.2 By Vector Type
8.2.1 Viral Vector Market, By Type
8.3 By Application
8.4 By End User
8.5 By Country
8.5.1 China Gene Therapy Market
8.5.1.1 By type
8.5.1.2 By vector type
8.5.1.2.1 Viral vector market, by type
8.5.1.3 By application
8.5.1.4 By end user
8.5.2 Japan Gene Therapy Market
8.5.2.1 By type
8.5.2.2 By vector type
8.5.2.2.1 Viral vector market, by type
8.5.2.3 By application
8.5.2.4 By end user
8.5.3 India Gene Therapy Market
8.5.3.1 By type
8.5.3.2 By vector type
8.5.3.2.1 Viral vector market, by type
8.5.3.3 By application
8.5.3.4 By end user
8.5.4 South Korea Gene Therapy Market
8.5.4.1 By type
8.5.4.2 By vector type
8.5.4.2.1 Viral vector market, by type
8.5.4.3 By application
8.5.4.4 By end user
Chapter 9. LATAM Market Size and Forecast
9.1 By Type
9.2 By Vector Type
9.2.1 Viral Vector Market, by Type
9.3 By Application
9.4 By End User
9.5 By Country
Chapter 10. MEA Market Size and Forecast
10.1 By Type
10.2 By Vector Type
10.2.1 Viral Vector Market, By Type
10.3 By Application
10.4 By End User
10.5 By Country
Chapter 11. Competitive Landscape
11.1 Product Benchmarking of Key Players
11.2 Strategic Developments of Key Players
11.2.1 Product Approval/Launch
11.2.2 Acquisitions
11.2.3 Collaboration and Partnerships
11.2.4 Other Developments
Chapter 12. Company Profiles
12.1 Spark Therapeutics Inc.
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.2 bluebird bio Inc.
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.3 Orchard Therapeutics plc
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
12.4 Amgen Inc.
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.4.2.1 Marketed products
12.4.2.2 Pipeline products
12.4.3 Key Financial Summary
12.5 REGENXBIO Inc.
12.5.1 Business Overview
12.5.2 Product and Service Offerings
12.5.3 Key Financial Summary
12.6 Thermo Fisher Scientific Inc.
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.3 Key Financial Summary
12.7 Applied Genetic Technologies Corporation
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
12.8 Pfizer Inc.
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
12.9 Adverum Biotechnologies Inc.
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.10 Novartis AG
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
Chapter 13. Appendix
13.1 Abbreviations
13.2 Sources and References
13.3 Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 5 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 6 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 8 GLOBAL VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 9 GLOBAL VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 10 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 11 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 12 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 13 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 14 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2014–2019)
TABLE 15 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2020–2030)
TABLE 16 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 17 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 18 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 19 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 20 NORTH AMERICA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 21 NORTH AMERICA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 22 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 23 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 24 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 25 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 26 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)
TABLE 27 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)
TABLE 28 U.S. GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 29 U.S. GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 30 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 31 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 32 U.S. VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 33 U.S. VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 34 U.S. GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 35 U.S. GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 36 U.S. GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 37 U.S. GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 38 CANADA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 39 CANADA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 40 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 41 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 42 CANADA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 43 CANADA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 44 CANADA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 45 CANADA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 46 CANADA GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 47 CANADA GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 48 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 49 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 50 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 51 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 52 EUROPE VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 53 EUROPE VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 54 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 55 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 56 EUROPE GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 57 EUROPE GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 58 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)
TABLE 59 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)
TABLE 60 GERMANY GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 61 GERMANY GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 62 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 63 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 64 GERMANY VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 65 GERMANY VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 66 GERMANY GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 67 GERMANY GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 68 GERMANY GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 69 GERMANY GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 70 U.K. GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 71 U.K. GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 72 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 73 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 74 U.K. VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 75 U.K. VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 76 U.K. GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 77 U.K. GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 78 U.K. GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 79 U.K. GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 80 FRANCE GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 81 FRANCE GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 82 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 83 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 84 FRANCE VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 85 FRANCE VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 86 FRANCE GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 87 FRANCE GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 88 FRANCE GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 89 FRANCE GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 90 ITALY GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 91 ITALY GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 92 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 93 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 94 ITALY VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 95 ITALY VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 96 ITALY GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 97 ITALY GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 98 ITALY GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 99 ITALY GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 100 SPAIN GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 101 SPAIN GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 102 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 103 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 104 SPAIN VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 105 SPAIN VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 106 SPAIN GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 107 SPAIN GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 108 SPAIN GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 109 SPAIN GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 110 APAC GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 111 APAC GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 112 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 113 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 114 APAC VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 115 APAC VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 116 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 117 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 118 APAC GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 119 APAC GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 120 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)
TABLE 121 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)
TABLE 122 CHINA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 123 CHINA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 124 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 125 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 126 CHINA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 127 CHINA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 128 CHINA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 129 CHINA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 130 CHINA GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 131 CHINA GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 132 JAPAN GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 133 JAPAN GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 134 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 135 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 136 JAPAN VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 137 JAPAN VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 138 JAPAN GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 139 JAPAN GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 140 JAPAN GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 141 JAPAN GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 142 INDIA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 143 INDIA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 144 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 145 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 146 INDIA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 147 INDIA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 148 INDIA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 149 INDIA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 150 INDIA GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 151 INDIA GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 152 SOUTH KOREA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 153 SOUTH KOREA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 154 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 155 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 156 SOUTH KOREA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 157 SOUTH KOREA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 158 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 159 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 160 SOUTH KOREA GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 161 SOUTH KOREA GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 162 LATAM GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 163 LATAM GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 164 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 165 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 166 LATAM VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 167 LATAM VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 168 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 169 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 170 LATAM GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 171 LATAM GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 172 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)
TABLE 173 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)
TABLE 174 MEA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)
TABLE 175 MEA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)
TABLE 176 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)
TABLE 177 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)
TABLE 178 MEA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)
TABLE 179 MEA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)
TABLE 180 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)
TABLE 181 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)
TABLE 182 MEA GENE THERAPY MARKET, BY END USER, $M (2014–2019)
TABLE 183 MEA GENE THERAPY MARKET, BY END USER, $M (2020–2030)
TABLE 184 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)
TABLE 185 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)
TABLE 186 SPARK THERAPEUTICS INC. – AT A GLANCE
TABLE 187 BLUEBIRD BIO INC. – AT A GLANCE
TABLE 188 PIPELINE PRODUCTS
TABLE 189 ORCHARD THERAPEUTICS PLC – AT A GLANCE
TABLE 190 ORCHARD THERAPEUTICS PLC – KEY FINANCIAL SUMMARY
TABLE 191 AMGEN INC. – AT A GLANCE
TABLE 192 PIPELINE PRODUCTS
TABLE 193 AMGEN INC. – KEY FINANCIAL SUMMARY
TABLE 194 REGENXBIO INC. – AT A GLANCE
TABLE 195 REGENXBIO INC. – KEY FINANCIAL SUMMARY
TABLE 198 APPLIED GENETIC TECHNOLOGIES CORPORATION – AT A GLANCE
TABLE 199 APPLIED GENETIC TECHNOLOGIES CORPORATION – KEY FINANCIAL SUMMARY
TABLE 200 PFIZER INC. – AT A GLANCE
TABLE 201 PFIZER INC. – KEY FINANCIAL SUMMARY
TABLE 202 ADVERUM BIOTECHNOLOGIES INC. – AT A GLANCE
TABLE 203 NOVARTIS AG – AT A GLANCE
TABLE 204 NOVARTIS AG – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 RESEARCH SCOPE
FIG 2 RESEARCH METHODOLOGY
FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
FIG 4 DATA TRIANGULATION APPROACH
FIG 5 GLOBAL GENE THERAPY MARKET SUMMARY
FIG 6 BARGAINING POWER OF BUYERS
FIG 7 BARGAINING POWER OF SUPPLIERS
FIG 8 INTENSITY OF RIVALRY
FIG 9 THREAT OF NEW ENTRANTS
FIG 10 THREAT OF SUBSTITUTES
FIG 11 GLOBAL GENE THERAPY MARKET SNAPSHOT, CAGR (2020-2030)
FIG 12 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2014–2030)
FIG 13 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)
FIG 14 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)
FIG 15 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2014–2030)
FIG 16 MAJOR MARKETS FOR GENE THERAPY
FIG 17 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2014–2030)
FIG 18 NORTH AMERICA GENE THERAPY MARKET SNAPSHOT
FIG 19 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2014–2030)
FIG 20 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)
FIG 21 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)
FIG 22 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2014–2030)
FIG 23 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)
FIG 24 EUROPE GENE THERAPY MARKET SNAPSHOT
FIG 25 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2014–2030)
FIG 26 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)
FIG 27 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)
FIG 28 EUROPE GENE THERAPY MARKET, BY END USER, $M (2014–2030)
FIG 29 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)
FIG 30 APAC GENE THERAPY MARKET SNAPSHOT
FIG 31 APAC GENE THERAPY MARKET, BY TYPE, $M (2014–2030)
FIG 32 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)
FIG 33 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)
FIG 34 APAC GENE THERAPY MARKET, BY END USER, $M (2014–2030)
FIG 35 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)
FIG 36 LATAM GENE THERAPY MARKET SNAPSHOT
FIG 37 LATAM GENE THERAPY MARKET, BY TYPE, $M (2014–2030)
FIG 38 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)
FIG 39 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)
FIG 40 LATAM GENE THERAPY MARKET, BY END USER, $M (2014–2030)
FIG 41 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)
FIG 42 MEA GENE THERAPY MARKET SNAPSHOT
FIG 43 MEA GENE THERAPY MARKET, BY TYPE, $M (2014–2030)
FIG 44 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)
FIG 45 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)
FIG 46 MEA GENE THERAPY MARKET, BY END USER, $M (2014–2030)
FIG 47 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)
FIG 48 PRODUCT BENCHMARKING OF KEY PLAYERS
FIG 49 AMGEN INC. – REVENUE SPLIT BY MARKETED PRODUCTS AND GEOGRAPHY (2019)
FIG 50 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 51 PFIZER INC. – REVENUE SPLIT BY OPERATING SEGMENT AND GEOGRAPHY (2019)
FIG 52 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws